Alpha Teknova (NASDAQ:TKNO) Posts Earnings Results

Alpha Teknova (NASDAQ:TKNO) announced its quarterly earnings results on Wednesday. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.02, FiscalAI reports. The firm had revenue of $12.19 million during the quarter, compared to the consensus estimate of $10.96 million. Alpha Teknova had a negative net margin of 41.07% and a negative return on equity of 24.32%.

Here are the key takeaways from Alpha Teknova’s conference call:

• Second-quarter revenue rose 18% to a record $12 million, with growth broad-based across customers and major markets aside from cell and gene therapy. Gross margin improved to 40.1%, while free cash outflow declined sharply to $0.6 million from $2.3 million a year earlier.
• Teknova raised 2026 revenue guidance to $45 million-$47 million, implying approximately 14% growth at the midpoint, and now expects full-year free cash outflow below $8 million.
• Management cited potential longer-term growth from more than 70 therapies and diagnostics in clinical trials, improving biotech funding, and commercial investments, but said the funding benefit has not yet reached revenue and expects most sales impact from the commercial buildout in early 2027.
• Cell and gene therapy demand remains muted, while operating expenses are expected to remain at least $8 million per quarter through year-end. The company still expects adjusted EBITDA to turn positive only after reaching approximately $52 million-$57 million in annualized revenue, and its 2027 target remains in the low-$50-million range.
• The company officially launched Build-Tek, an AI-powered custom-product configurator intended to shorten custom order design from weeks to a few business days and encourage catalog customers to adopt higher-value custom products; management expects it to support growth rather than generate direct software fees.

Alpha Teknova Price Performance

NASDAQ:TKNO traded up $0.09 during mid-day trading on Wednesday, reaching $5.61. The stock had a trading volume of 128,778 shares, compared to its average volume of 124,971. Alpha Teknova has a 12 month low of $1.91 and a 12 month high of $6.68. The stock has a 50-day simple moving average of $5.17 and a two-hundred day simple moving average of $3.71. The company has a debt-to-equity ratio of 0.20, a current ratio of 4.59 and a quick ratio of 3.60. The stock has a market capitalization of $300.75 million, a PE ratio of -17.53 and a beta of 0.64.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in TKNO. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in shares of Alpha Teknova in the 2nd quarter valued at $29,000. JPMorgan Chase & Co. increased its holdings in Alpha Teknova by 123.1% during the 2nd quarter. JPMorgan Chase & Co. now owns 8,163 shares of the company’s stock worth $40,000 after purchasing an additional 4,504 shares in the last quarter. Larson Financial Group LLC raised its position in Alpha Teknova by 58.5% in the 3rd quarter. Larson Financial Group LLC now owns 9,387 shares of the company’s stock valued at $58,000 after buying an additional 3,464 shares during the last quarter. XTX Topco Ltd bought a new position in shares of Alpha Teknova during the fourth quarter valued at about $77,000. Finally, Sherbrooke Park Advisers LLC bought a new position in shares of Alpha Teknova during the 3rd quarter worth approximately $94,000. Institutional investors own 13.81% of the company’s stock.

Analyst Ratings Changes

TKNO has been the topic of several recent analyst reports. Roth Capital started coverage on shares of Alpha Teknova in a research note on Wednesday. They set a “buy” rating and a $7.00 price objective on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Alpha Teknova in a research note on Friday, July 17th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Alpha Teknova presently has an average rating of “Hold” and an average target price of $7.00.

About Alpha Teknova

Alpha Teknova, Inc (NASDAQ: TKNO) is a life science tools and reagents company that develops, manufactures and distributes proprietary products to support research, drug discovery and biomanufacturing. Its offerings target academic institutions, pharmaceutical and biotechnology firms, and diagnostic developers, with a focus on high-purity reagents and optimized workflows designed to accelerate molecular biology and protein science applications.

The company’s portfolio includes molecular biology reagents, cell culture buffers, in vitro translation kits, custom recombinant proteins, high-throughput screening buffers and other specialized formulations.